Restasis and Eye injury - a phase IV clinical study of FDA data

Summary:

Eye injury is reported as a side effect among people who take Restasis (cyclosporine), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Zyrtec, and have Parkinson's disease.

The phase IV clinical study analyzes which people have Eye injury when taking Restasis. It is created by eHealthMe based on reports of 34,716 people who have side effects when taking Restasis from the FDA, and is updated regularly.

What is Restasis?

Restasis has active ingredients of cyclosporine. It is often used in dry eyes. eHealthMe is studying from 35,199 Restasis users. Check the latest studies of Restasis.

What is Eye injury?

Eye injury is found to be associated with 444 drugs and 467 conditions by eHealthMe. Check the latest studies of Eye injury.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 24, 2026

34,716 people reported to have side effects when taking Restasis.
Among them, 58 people (0.17%) have Eye injury.

Among these 58 people:

How long have people been on Restasis when they have Eye injury? *

What is the gender of people who have Eye injury when taking Restasis? *

female: 87.5 %
male: 12.5 %

What is the age of people who have Eye injury when taking Restasis? *

What are other drugs people take besides Restasis? *

What are other side effects people have besides Eye injury? *

Eye Irritation: 10 people, 17.24%
Eye Pain: 9 people, 15.52%
Fall: 8 people, 13.79%
Visual Acuity Reduced (reduced clearness of vision): 8 people, 13.79%
Nausea (feeling of having an urge to vomit): 8 people, 13.79%
Visual Impairment: 7 people, 12.07%
Cataract (clouding of the lens inside the eye): 7 people, 12.07%
Ocular Hyperaemia (an abnormally large amount of blood in eye): 7 people, 12.07%
Fatigue (feeling of tiredness): 6 people, 10.34%
Vision Blurred: 6 people, 10.34%

What are the existing conditions these people have? *

Glaucoma (increased fluid pressure in the eye with vision loss): 3 people, 5.17%
Multiple Allergies (allergy to multiple agents): 3 people, 5.17%
Parkinson's Disease: 3 people, 5.17%
Cholinergic Syndrome (symptoms of increased cholinergic stimulation): 2 people, 3.45%
Eye Disorder: 2 people, 3.45%
Insomnia (sleeplessness): 2 people, 3.45%
Iron Deficiency: 2 people, 3.45%
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 2 people, 3.45%
Diabetes: 2 people, 3.45%
Depression: 2 people, 3.45%

* Approximation only. Some reports may have incomplete information.

Do you take Restasis and have Eye injury?

- Check whether Eye injury is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Restasis:

Restasis (35,199 reports)

Eye injury treatments and more:

Eye injury (3,481 reports)

Browse all side effects of Restasis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Eye injury:

Eye injury (444 drugs)

Browse all the conditions that are associated with Eye injury:

Eye injury (467 conditions)

Related publications that referenced our studies

O’Brien FE, O’Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF, "The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram", Behavioural brain research, 2014 Mar .
O’Brien FE, O’Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF, "The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram", Behavioural brain research, 2014 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on cyclosporine (the active ingredients of Restasis) and Restasis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.